PMID- 34350199
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210806
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: 
      Real-World Evidence Based on Big Data for Risk Management.
PG  - 700014
LID - 10.3389/fmed.2021.700014 [doi]
LID - 700014
AB  - Background: Two coronavirus disease 2019 (COVID-19) vaccines have received 
      emergency use authorizations in the U.S. However, the safety of these vaccines in 
      the real-world remains unknown. Methods: We reviewed adverse events (AEs) 
      following COVID-19 vaccination among adults in the Vaccine Adverse Event 
      Reporting System (VAERS) from December 14, 2020, through January 22, 2021. We 
      compared the top 10 AEs, serious AEs, along with office and emergency room (ER) 
      visits by age (18-64 years, >/=65 years) and gender (female, male). Results: There 
      were age and gender disparities among adults with AEs following COVID-19 
      vaccination. Compared to younger adults aged between 18 and 64 years, older 
      adults were more likely to report serious AEs, death, permanent disability, and 
      hospitalization. Males were more likely to report serious AEs, death, and 
      hospitalization compared to females. Conclusions: COVID-19 vaccines are generally 
      safe but possible age and gender disparities in reported AEs may exist.
CI  - Copyright (c) 2021 Xiong, Yuan, Li, Jiang and Lu.
FAU - Xiong, Xiaomo
AU  - Xiong X
AD  - Department of Clinical Pharmacy and Outcomes Sciences, University of South 
      Carolina, Columbia, SC, United States.
FAU - Yuan, Jing
AU  - Yuan J
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
FAU - Li, Minghui
AU  - Li M
AD  - Department of Clinical Pharmacy and Translational Science, University of 
      Tennessee Health Science Center, Memphis, TN, United States.
FAU - Jiang, Bin
AU  - Jiang B
AD  - Department of Administrative and Clinical Pharmacy, School of Pharmaceutical 
      Sciences, Health Science Center, Peking University, Beijing, China.
FAU - Lu, Z Kevin
AU  - Lu ZK
AD  - Department of Clinical Pharmacy and Outcomes Sciences, University of South 
      Carolina, Columbia, SC, United States.
LA  - eng
PT  - Journal Article
DEP - 20210719
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8326508
OTO - NOTNLM
OT  - COVID-19
OT  - mRNA vaccines
OT  - real-world data
OT  - real-world study
OT  - vaccine adverse event reporting system
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
PMCR- 2021/07/19
CRDT- 2021/08/05 06:30
PHST- 2021/04/25 00:00 [received]
PHST- 2021/06/25 00:00 [accepted]
PHST- 2021/08/05 06:30 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
PHST- 2021/07/19 00:00 [pmc-release]
AID - 10.3389/fmed.2021.700014 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Jul 19;8:700014. doi: 10.3389/fmed.2021.700014. 
      eCollection 2021.